Research Papers:

Discovery and validation of the tumor-suppressive function of long noncoding RNA PANDA in human diffuse large B-cell lymphoma through the inactivation of MAPK/ERK signaling pathway

Yingjun Wang, Mingzhi Zhang _, Huanan Xu, Yifei Wang, Zhaoming Li, Yu Chang, Xinhuan Wang, Xiaorui Fu, Zhiyuan Zhou, Siyuan Yang, Bei Wang and Yufeng Shang

PDF  |  HTML  |  How to cite

Oncotarget. 2017; 8:72182-72196. https://doi.org/10.18632/oncotarget.20053

Metrics: PDF 2859 views  |   HTML 2864 views  |   ?  


Yingjun Wang1, Mingzhi Zhang1, Huanan Xu2, Yifei Wang3, Zhaoming Li1, Yu Chang1, Xinhuan Wang1, Xiaorui Fu1, Zhiyuan Zhou1, Siyuan Yang1, Bei Wang1 and Yufeng Shang1

1Department of Oncology, The First Affiliated Hospital of Zhengzhou University, Lymphoma Diagnosis and Treatment Center of Henan Province, Zhengzhou, Henan, China

2Department of Anorectal Surgery, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China

3Department of Ultrasonography, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China

Correspondence to:

Mingzhi Zhang, email: [email protected]

Keywords: lncRNAs, diffuse large B-cell lymphoma, lncRNA PANDA, p53, MAPK/ERK

Received: June 30, 2017     Accepted: July 26, 2017     Published: August 07, 2017


Diffuse large B-cell lymphoma (DLBCL) is one of the leading causes of cancer-related mortality, and responds badly to existing treatment. Thus, it is of urgent need to identify novel prognostic markers and therapeutic targets of DLBCL. Recent studies have shown that long non-coding RNAs (lncRNAs) play an important role in the development of cancer. By using the next generation HiSeq sequencing assay, we determined lncRNAs exhibiting differential expression between DLBCL patients and healthy controls. Then, RT-qPCR was performed for identification in clinical samples and cell materials, and lncRNA PANDA was verified to be down-regulated in DLBCL patients and have considerable diagnostic potential. In addition, decreased serum PANDA level was correlated to poorer clinical outcome and lower overall survival in DLBCL patients. Subsequently, we determined the experimental role of lncRNA PANDA in DLBCL progression. Luciferase reporter assay and chromatin immunoprecipitation assay suggested that lncRNA PANDA was induced by p53 and p53 interacts with the promoter region of PANDA. Cell functional assay further indicated that PANDA functioned as a tumor suppressor gene through the suppression of cell growth by a G0/G1 cell cycle arrest in DLBCL. More importantly, Cignal Signal Transduction Reporter Array and western blot assay showed that lncRNA PANDA inactivated the MAPK/ERK signaling pathway. In conclusion, our integrated approach demonstrates that PANDA in DLBCL confers a tumor suppressive function through inhibiting cell proliferation and silencing MAPK/ERK signaling pathway. Thus, PANDA may be a promising therapeutic target for patients with DLBCL.

Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 20053